EXCLUSIVE: Beckley Psytech’s CEO Cosmo Feilding Mellen on raising US$80 million
Beckley Psytech has announced the completion of its oversubscribed financing round, with US$80m raised. The company is currently conducting clinical trials with low doses of psilocybin, as a pharmacological intervention without a psychotherapy component. There are also plans to start Phase I clinical trials into its intranasal 5-MeO-DMT formulation later this year.
PSYCH spoke with Beckley Psytech’s CEO Cosmo Feilding Mellen, regarding the company’s investors, mission and revived interest in the field – dubbed the psychedelic renaissance.Read More